Newer Agent Use in Obese and Overweight Adults

With more than 40% of U.S. adults affected by obesity and an additional 31% considered overweight, the weight-management landscape is constantly evolving. In addition to metabolic, physical, and psychosocial complications, obesity and overweight result in increased healthcare expenditures. Lifelong individualized management is necessary due to the multifactorial causes of obesity and overweight. In conjunction with lifestyle modifications, pharmacologic and surgical methods may be used to achieve weight-loss goals. Newer agents, such as glucagon-like peptide-1 (GLP-1) receptor agonists and combination GLP-1 receptor/glucose– dependent insulinotropic polypeptide agonists, provide significant weight-loss benefits, but patients have been challenged by accessibility issues due to cost/coverage and drug shortages. O².